论文部分内容阅读
目的:研究并分析表柔比星联合紫杉醇对三阴性乳腺癌患者的临床治疗效果。方法:以我院2012年8月-2015年3月期间共收治的72例三阴性乳腺癌患者为研究对象,并将其随机分组,对照组的36例患者单用表柔比星辅助化疗方案进行治疗,观察组的36例患者运用表柔比星联合紫杉醇辅助化疗方案进行治疗,对比两组患者的临床治疗效果。结果:对照组患者病情完全缓解5例,部分缓7例,近期临床治疗总有效率为52.78%,观察组患者病情完全缓解10例,部分缓解9例,近期临床治疗总有效率为77.78%,两组之间的差异具有显著性(P<0.05)。结论:对于三阴性乳腺癌患者而言,运用表柔比星联合紫杉醇辅助化疗方案进行治疗疗效确切,安全性好,值得推广。
Objective: To study and analyze the clinical efficacy of epirubicin and paclitaxel in triple negative breast cancer patients. Methods: Totally 72 patients with triple-negative breast cancer who were treated in our hospital from August 2012 to March 2015 were randomly divided into three groups: 36 patients in the control group received epirubicin adjuvant chemotherapy alone 36 patients in the observation group were treated with epirubicin and paclitaxel-adjuvant chemotherapy, and the clinical effects of the two groups were compared. Results: The patients in the control group were completely relieved in 5 cases and partially in 7 cases. The total effective rate in the recent clinical treatment was 52.78%. In the observation group, 10 cases were completely relieved and 9 cases partially relieved. The total effective rate in the recent clinical treatment was 77.78% The difference between the two groups was significant (P <0.05). Conclusion: For patients with triple-negative breast cancer, epirubicin plus paclitaxel adjuvant chemotherapy regimen is effective and safe, and is worth promoting.